Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA Approves First Gene Therapy for Hereditary Disease

The FDA has approved Luxturna, a gene therapy that treats patients with an inherited form of vision loss.

Luxturna / Image: Spark Therapeutics
Luxturna / Image: Spark Therapeutics

A December 19th LA Times article reported that the FDA has approved gene therapy to fix mutations that lead to progressive blindness. The drug, Luxturna, is a treatment for retinal dystrophy caused by a genetic mutation. It is the first therapy cleared in the U.S. to treat a genetic disease other than cancer, making it a landmark event.

“Gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses,” said Dr. Scott Gottlieb, commissioner of the FDA. “We’re at a turning point when it comes to this novel form of therapy.”

The treatment is injected into the sub-retinal portion of the eye and a normal RPE65 gene is ferried into the patient’s retinal cells by a common cold virus that has been genetically modified to not make the patient sick.

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Researched List: Blister Machines for Life Sciences